Study Summary
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases PM. It has been demonstrated to be superior to CT for patients with known peritoneal disease from colorectal and gynaecological malignancies as a staging tool for cytoreductive surgery. It was also demonstrated to be superior for the detection of PM for gastric cancer patients otherwise considered with a resectable tumor. However, the literature is scarce on the role of DWI/MRI in the detection of peritoneal recurrence for patients with high-risk features, either colorectal cancer (CRC) or appendiceal neoplasms (AN). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT and diagnostic laparoscopy for detection of PM in the follow-up of patients presenting with CRC or AN and high-risk features for peritoneal recurrence and evaluate how it correlates with intraoperative findings.
Eligible Conditions
- Peritoneal Carcinomatosis
- Colorectal Cancer
- Appendiceal Neoplasm
- Peritoneal Metastases
- Appendiceal Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 1 Secondary · Reporting Duration: 36 months
24 months
Peritoneal findings
36 months
Early distant recurrence
Early peritoneal recurrence
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
DWI-High Risk
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: DWI-High Risk · No Placebo Group · N/A
DWI-High Risk
DiagnosticTest
Experimental Group · 1 Intervention: Whole-body diffusion-weighted magnetic resonance imaging · Intervention Types: DiagnosticTestTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 36 months
Who is running the clinical trial?
Laval UniversityLead Sponsor
391 Previous Clinical Trials
164,918 Total Patients Enrolled
2 Trials studying Peritoneal Carcinomatosis
70 Patients Enrolled for Peritoneal Carcinomatosis
Ciusss de L'Est de l'Île de MontréalOTHER
50 Previous Clinical Trials
3,309 Total Patients Enrolled
1 Trials studying Peritoneal Carcinomatosis
30 Patients Enrolled for Peritoneal Carcinomatosis
Alexandre Brind'Amour, MDPrincipal InvestigatorLaval University
2 Previous Clinical Trials
70 Total Patients Enrolled
2 Trials studying Peritoneal Carcinomatosis
70 Patients Enrolled for Peritoneal Carcinomatosis
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Synchronous peritoneal metastases resected at index surgery.
Synchronous ovarian metastases resected at index surgery.
You have a perforated primary tumor.
You are fit for cytoreductive surgery, if required.
References
- Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010 May;17(5):1330-6. doi: 10.1245/s10434-009-0866-x. Epub 2009 Dec 22.
- Tiselius C, Kindler C, Shetye J, Letocha H, Smedh K. Computed Tomography Follow-Up Assessment of Patients with Low-Grade Appendiceal Mucinous Neoplasms: Evaluation of Risk for Pseudomyxoma Peritonei. Ann Surg Oncol. 2017 Jul;24(7):1778-1782. doi: 10.1245/s10434-016-5623-3. Epub 2017 May 4.
- Orr CE, Yantiss RK. Controversies in appendiceal pathology: mucinous and goblet cell neoplasms. Pathology. 2022 Mar;54(2):167-176. doi: 10.1016/j.pathol.2021.09.003. Epub 2021 Nov 23. Review.
- Elias D, Honore C, Dumont F, Ducreux M, Boige V, Malka D, Burtin P, Dromain C, Goere D. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011 Aug;254(2):289-93. doi: 10.1097/SLA.0b013e31822638f6.
- Soucisse ML, Lansom J, Alshahrani MS, Morris DL. Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. ANZ J Surg. 2020 Oct;90(10):1888-1894. doi: 10.1111/ans.16185. Epub 2020 Aug 5. Review.
- van 't Sant I, van Eden WJ, Engbersen MP, Kok NFM, Woensdregt K, Lambregts DMJ, Shanmuganathan S, Beets-Tan RGH, Aalbers AGJ, Lahaye MJ. Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br J Surg. 2019 Mar;106(4):491-498. doi: 10.1002/bjs.10989. Epub 2018 Oct 24.
- Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr;66(4):683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27.
- Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. Ann Surg Oncol. 2020 Jun;27(6):1753-1760. doi: 10.1245/s10434-020-08316-w. Epub 2020 Apr 13.
- Elekonawo FMK, Starremans B, Laurens ST, Bremers AJA, de Wilt JHW, Heijmen L, de Geus-Oei LF. Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer? Abdom Radiol (NY). 2020 Feb;45(2):301-306. doi: 10.1007/s00261-019-02268-w.
- Dong, Li, Kuo Li, and Taisong Peng. 2021. “Diagnostic Value of Diffusion-weighted Imaging/magnetic Resonance Imaging for Peritoneal Metastasis from Malignant Tumor”. Medicine. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/md.0000000000024251.
- Namimoto T, Awai K, Nakaura T, Yanaga Y, Hirai T, Yamashita Y. Role of diffusion-weighted imaging in the diagnosis of gynecological diseases. Eur Radiol. 2009 Mar;19(3):745-60. doi: 10.1007/s00330-008-1185-5. Epub 2008 Oct 7.
- Massalou D, Benizri E, Chevallier A, Duranton-Tanneur V, Pedeutour F, Benchimol D, Bereder JM. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017 Feb;213(2):377-387. doi: 10.1016/j.amjsurg.2016.03.008. Epub 2016 Aug 5.
- Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, Brandt A, Bremers AJA, Burger JWA, Fabry HFJ, Ferenschild F, Festen S, van Grevenstein WMU, Hemmer PHJ, de Hingh IHJT, Kok NFM, Musters GD, Schoonderwoerd L, Tuynman JB, van de Ven AWH, van Westreenen HL, Wiezer MJ, Zimmerman DDE, van Zweeden AA, Dijkgraaf MGW, Tanis PJ; COLOPEC collaborators group. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):761-770. doi: 10.1016/S2468-1253(19)30239-0. Epub 2019 Jul 29.
- Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gomez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, Gonzalez-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012 Jul 10;30(20):2449-56. doi: 10.1200/JCO.2011.39.7166. Epub 2012 May 21.
- Hegg KS, Mack LA, Bouchard-Fortier A, Temple WJ, Gui X. Macroscopic and microscopic characteristics of low grade appendiceal mucinous neoplasms (LAMN) on appendectomy specimens and correlations with pseudomyxoma peritonei development risk. Ann Diagn Pathol. 2020 Oct;48:151606. doi: 10.1016/j.anndiagpath.2020.151606. Epub 2020 Aug 21.
- Huan, Zhang, Dai Weixing, Fu Caixia, Yan Xu, Stemmer Alto, Tong Tong, and Cai Guoxiang. 2018. “Diagnostic Value of Whole-body MRI with Diffusion-weighted Sequence for Detection of Peritoneal Metastases in Colorectal Malignancy”. Cancer Biology & Medicine. China Anti-cancer Association. doi:10.20892/j.issn.2095-3941.2017.0162.
- Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010 Nov 1;102(6):565-70. doi: 10.1002/jso.21601.
- Goere D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech JJ, Kianmanesh R, Carretier M, Marchal F, Arvieux C, Brigand C, Meeus P, Rat P, Durand-Fontanier S, Mariani P, Lakkis Z, Loi V, Pirro N, Sabbagh C, Texier M, Elias D; BIG-RENAPE group. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020 Sep;21(9):1147-1154. doi: 10.1016/S1470-2045(20)30322-3. Epub 2020 Jul 24.
- Reiter S, Rog CJ, Alassas M, Ong E. Progression to pseudomyxoma peritonei in patients with low grade appendiceal mucinous neoplasms discovered at time of appendectomy. Am J Surg. 2022 Jun;223(6):1183-1186. doi: 10.1016/j.amjsurg.2021.12.003. Epub 2021 Dec 3.
- Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan 1;28(1):63-8. doi: 10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum In: J Clin Oncol. 2010 Apr 1;28(10):1808.
- Brind'Amour A, Dubé P, Tremblay JF, Soucisse ML, Mack L, Bouchard-Fortier A, McCart JA, Govindarajan A, Bischof D, Haase E, Giacomantonio C, Hebbard P, Younan R, MacNeill A, Boulanger-Gobeil C, Sidéris L. Canadian guidelines on the management of colorectal peritoneal metastases. Curr Oncol. 2020 Dec;27(6):e621-e631. doi: 10.3747/co.27.6919. Epub 2020 Dec 1.
- De Vuysere, Sofie, Vincent Vandecaveye, Yves De Bruecker, Saskia Carton, Koen Vermeiren, Tim Tollens, Frederik De Keyzer, and Raphaëla Carmen Dresen. 2021. “Accuracy of Whole-body Diffusion-weighted MRI (WB-DWI/MRI) in Diagnosis, Staging and Follow-up of Gastric Cancer, in Comparison to CT: A Pilot Study”. BMC Medical Imaging. Springer Science and Business Media LLC. doi:10.1186/s12880-021-00550-2.
- Dresen, Raphaëla Carmen, Sofie De Vuysere, Frederik De Keyzer, Eric Van Cutsem, Hans Prenen, Ragna Vanslembrouck, Gert De Hertogh, Albert Wolthuis, André D’Hoore, and Vincent Vandecaveye. 2019. “Whole-body Diffusion-weighted MRI for Operability Assessment in Patients with Colorectal Cancer and Peritoneal Metastases”. Cancer Imaging. Springer Science and Business Media LLC. doi:10.1186/s40644-018-0187-z.
- Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int. 2014;2014:782890. doi: 10.1155/2014/782890. Epub 2014 Mar 24.
- Honore C, Goere D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013 Jan;20(1):183-92. doi: 10.1245/s10434-012-2473-5. Epub 2012 Oct 23.
- Brind'Amour A, Dube P, Tremblay JF, Soucisse ML, Mack L, Bouchard-Fortier A, McCart JA, Govindarajan A, Bischof D, Haase E, Giacomantonio C, Hebbard P, Younan R, MacNeill A, Boulanger-Gobeil C, Sideris L. Canadian guidelines on the management of colorectal peritoneal metastases. Curr Oncol. 2020 Dec;27(6):e621-e631. doi: 10.3747/co.27.6919. Epub 2020 Dec 1.
- Orr CE, Yantiss RK. Controversies in appendiceal pathology: mucinous and goblet cell neoplasms. Pathology. 2022 Mar;54(2):167-176. doi: 10.1016/j.pathol.2021.09.003. Epub 2021 Nov 23.
- Soucisse ML, Lansom J, Alshahrani MS, Morris DL. Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. ANZ J Surg. 2020 Oct;90(10):1888-1894. doi: 10.1111/ans.16185. Epub 2020 Aug 5.
- Alexandre Brind'Amour 2022. "Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05623787.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments